Andrew leads the engineering device development team and coordinates multifunctional groups across the organization with a focus on advancement of the Alcyone Therapeutics Precision Delivery portfolio. Andrew has over 19 years of experience bringing innovative technologies from concept to market, through regulatory clearance and product launch. Andrew first joined Alcyone to lead the development of a Hydrocephalus shunt technology, known as ReFlow, which was spun out to form Anuncia Inc. in 2018. Prior to joining Alcyone Therapeutics, Andrew held positions at Accellent Inc. (now Integer) and Ranfac Corporation. Andrew holds numerous patents on a wide range of product families spanning over 19 years of cutting-edge technology development. Andrew holds a BS in Mechanical Engineering, and certificates in Medical Device Regulatory Affairs from Northeastern University and in Medical Device Management from Worcester Polytechnic Institute.